Patents by Inventor Ibrahim M. El-Sherbiny

Ibrahim M. El-Sherbiny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10245244
    Abstract: Pharmaceutical formulations are described for use in the treatment of pulmonary arterial hypertension (PAH). The formulations comprise polymeric nanoparticles encapsulated within crosslinked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of PAH loaded within them (for example, prostacyclin synthetic analogs, PPAR ? agonists and NO donors). Preferred formulations are inhalable, dry powder pharmaceutical formulations, which are able to swell on administration to the lungs of a patient.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: April 2, 2019
    Assignee: HEART BIOTECH PHARMA LIMITED
    Inventors: Magdi Habib Yacoub, Ibrahim M El Sherbiny
  • Patent number: 10092660
    Abstract: The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: October 9, 2018
    Assignee: STC.UNM
    Inventors: Hugh Smyth, Ibrahim M. El-Sherbiny
  • Patent number: 10034837
    Abstract: Therapeutic formulations are described for use in the treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza and acute myocardial infarction. The formulations comprise polymeric nanoparticles or polymeric nanoparticles encapsulated within cross-linked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza, acute myocardial infarction and heart failure. Preferred formulations are inhalable, dry powder therapeutic formulations, which are able to swell on administration to the lungs of a patient.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: July 31, 2018
    Assignee: HEART BIOTECH PHARMA LIMITED
    Inventors: Magdi Habib Yacoub, Ibrahim M. El-Sherbiny
  • Publication number: 20160374950
    Abstract: Therapeutic formulations are described for use in the treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza and acute myocardial infarction. The formulations comprise polymeric nanoparticles or polymeric nanoparticles encapsulated within cross-linked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza, acute myocardial infarction and heart failure. Preferred formulations are inhalable, dry powder therapeutic formulations, which are able to swell on administration to the lungs of a patient.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 29, 2016
    Inventors: Magdi Habib YACOUB, Ibrahim M. EL SHERBINY
  • Publication number: 20150196516
    Abstract: Pharmaceutical formulations are described for use in the treatment of pulmonary arterial hypertension (PAH). The formulations comprise polymeric nanoparticles encapsulated within crosslinked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of PAH loaded within them (for example, prostacyclin synthetic analogs, PPAR ? agonists and NO donors). Preferred formulations are inhalable, dry powder pharmaceutical formulations, which are able to swell on administration to the lungs of a patient.
    Type: Application
    Filed: January 9, 2015
    Publication date: July 16, 2015
    Inventors: Magdi Habib YACOUB, Ibrahim M. EL SHERBINY
  • Publication number: 20140141094
    Abstract: The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions.
    Type: Application
    Filed: April 25, 2012
    Publication date: May 22, 2014
    Applicant: STC. UNM
    Inventors: Hugh Smyth, Ibrahim M. El-Sherbiny
  • Patent number: 8652366
    Abstract: Disclosed are aerosol-mediated methods for synthesizing particles for biomedical and drug delivery applications. The method is based on the production of particles from sprayed polymeric micro or nano-droplets obtained by, for example, an air-jet nebulization process that is followed by gelation and/or hardening in a crosslinking fluid, non-solvent, precipitating solvent, or supercritical fluid.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: February 18, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Hugh D. C. Smyth, Ibrahim M. El-Sherbiny
  • Publication number: 20120108676
    Abstract: Disclosed are aerosol-mediated methods for synthesizing particles for biomedical and drug delivery applications. The method is based on the production of particles from sprayed polymeric micro or nano-droplets obtained by, for example, an air-jet nebulization process that is followed by gelation and/or hardening in a crosslinking fluid, non-solvent, precipitating solvent, or supercritical fluid.
    Type: Application
    Filed: November 1, 2011
    Publication date: May 3, 2012
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hugh D.C. Smyth, Ibrahim M. El-Sherbiny